Alessandra Ferrajoli
M.D. Anderson Cancer Center · UT M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alessandra Ferrajoli as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:33 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06967610 · Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).M.D. Anderson Cancer Center · recruiting · Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia (SLL) · principal investigator
- N/ANCT05879133 · HEALTH4CLL2: A Randomized Waitlist Control Trial of Behavioral Interventions in Patients With Chronic Lymphocytic LeukemiaM.D. Anderson Cancer Center · active not recruiting · Chronic Lymphocytic Leukemia · principal investigator
- Ph1/Ph2NCT05317936 · Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With VenetoclaxM.D. Anderson Cancer Center · terminated · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator
- Ph2NCT03128879 · Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLLM.D. Anderson Cancer Center · active not recruiting · Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT02225275 · Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaM.D. Anderson Cancer Center · terminated · Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT02131584 · Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic LeukemiaM.D. Anderson Cancer Center · active not recruiting · Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT01924169 · Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)M.D. Anderson Cancer Center · terminated · Hematologic Disorder · principal investigator
- Ph2NCT01446133 · Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)M.D. Anderson Cancer Center · active not recruiting · Leukemia, Lymphoma · principal investigator
- Ph2NCT01444716 · Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic LeukemiaM.D. Anderson Cancer Center · completed · Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT01002755 · Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaM.D. Anderson Cancer Center · completed · Chronic Lymphocytic Leukemia, Fatigue, Fever · principal investigator
- Ph2NCT00940342 · Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic LeukemiaM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph2NCT00759603 · Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic LeukemiaM.D. Anderson Cancer Center · completed · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator
- Ph2NCT00632359 · Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual DiseaseM.D. Anderson Cancer Center · completed · Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT00535873 · Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and OlderM.D. Anderson Cancer Center · completed · Leukemia, CLL, Chronic Lymphocytic Leukemia · principal investigator
- N/ANCT00503256 · Genetic Study of Chronic Lymphocytic Leukemia FamiliesM.D. Anderson Cancer Center · unknown · Leukemia · principal investigator
- Ph2NCT00381004 · FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic LeukemiaM.D. Anderson Cancer Center · completed · Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT00267059 · Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)M.D. Anderson Cancer Center · completed · Chronic Lymphocytic Leukemia, Leukemia · principal investigator
- Ph2NCT00102661 · Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic LeukemiaM.D. Anderson Cancer Center · completed · Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT00071396 · Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid DisordersM.D. Anderson Cancer Center · completed · Chronic Lymphocytic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026Named on NCT01444716, NCT01002755
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:33 UTC. The ranking covers the 200 most relevant of 136 PubMed records, and a shared surname and initials can bring in a namesake. All 136 on PubMed
- 551 citationsRCR 10.8
- Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.N Engl J Med · 2023454 citationsRCR 43.2
- Ibrutinib and Venetoclax for First-Line Treatment of CLL.N Engl J Med · 2019426 citationsRCR 15.0
- 404 citationsRCR 8.6
- 343 citationsRCR 7.9
- 330 citationsRCR 6.9
- 312 citationsRCR 6.4
- Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.Lancet Oncol · 2014294 citationsRCR 7.7
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.Lancet Haematol · 2020282 citationsRCR 11.3
- 279 citationsRCR 6.3